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From a public health perspective, some of the new insights into folic acid nutrition are of
significance. Folate intake recommendations vary under different conditions. Intake of 350 mg
is required to maintain plasma homocysteine levels, 650 mg for those with elevated plasma
homocysteine, about 400 mg for women planning to become pregnant and 4000 mg for those
with history of neural tube defect affected pregnancy. This raises the question whether the folate
intake is adequate for the general population, particularly in the vulnerable groups or whether
there is a need for scientists to take a fresh view of the requirements, recommended dietary
intakes, and consider intervention measures which will have impact on the folate nutritional
status. The recommendations should provide a margin of safety to allow for decreased intake,
increased requirements, individual variability and bioavailability of natural food folates. The
folate intake and nutriture in relation to India and other developing countries needs careful
consideration to reduce anemia, neural tube defects and possibly impact on the high incidence of
cardiovascular diseases.
Folate: Homocysteine: Health and disease: RDA: India
Folate is the generic term for compounds that have vitamin
activity similar to that of pteroylglutamic acid and is an
anti-anemic and growth factor. Folate acts as a co-enzyme
in several single carbon transfers leading to the biosynth-
esis of purine nucleotides and deoxythymidylic acid
essential for DNA and RNA synthesis. In general, rapidly
growing and multiplying cells require an adequate supply
of folate. As it participates in several biochemical
functions, it is important to consider conditions that
increase the risk of folate deficiency and its consequences.
Food folate — digestion, absorption and availability
Folate exists in many chemical forms (Wagner, 1996).
Mammals are unable to synthesize a pteridine ring, one of
the three groups of tetrahydrofolate; the other two groups
are p-aminobenzoate and glutamate. They obtain tetrahy-
drofolate from their diets or from microorganisms in their
intestinal tract. Naturally occurring folates, called food
folate (polyglutamyl chain) are present both in animal and
plant foods. Organ meats such as liver and egg yolk are
fairly good sources of folate and in the Indian context the
major sources are legumes and green leafy vegetables. The
intake of folate based on the NNMB (1999) suggested that
as per the existing recommendations more than 60 % of
folate nutrition is met from cereals and pulses (Fig. 1).
The intestinal absorption of folate occurs at the
monoglutamyl level. Therefore dietary folates, most of
which are polyglutamyl derivatives, undergo hydrolysis in
the gut to monoglutamates before absorption, across the
intestinal mucosa (Butterworth et al. 1969). In the absence
of protecting agents such as ascorbic acid and reduced
thiols, many labile folates may be lost during residence in
the acid peptic milieu of the stomach. Other food
constituents affect action of the intestinal hydrolases.
Absorption of monoglutamate predominantly occurs in
the duodenum and jejunum by an active transport in a
saturable pH dependent process. By far the majority of
intracellular folates are polyglutamates. In contrast, extra-
cellular folates are monoglutamates (Cossins, 1984). For
folate absorption, luminal digestion to the monoglutamyl
form by an intestinal enzyme known as folate conjugase
found in the brush border is the rate limiting step. This
enzyme is an exopeptidase and is activated by zinc
(Chandler et al. 1986). A second enzyme, intracellular
hydrolase, is found in the lysosomes of intestinal cells, has
a pH optimum of 4·5 and is an endopeptidase (Wang et al.
1986). The function of the former is believed to be
primarily in the digestion of dietary folates and that of the
latter is still unknown. Monoglutamates are present in
portal circulation, which is taken by the liver and converted
to polyglutamate derivatives and stored or released into the
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blood. In plasma, folate is bound primarily to albumin.
Cellular transport of folate is mediated through a number of
different folate transport systems.
Information on the availability of food folate is
fragmentary. The paucity of information stems primarily
from the complexity of dietary folates, their low levels,
presence of dietary inhibitors and the limited ability to
distinguish between newly absorbed folate and endogenous
folate. Seyoum & Selhub (1998) developed an in vitro
method based on the stability and susceptibility to intestinal
pteroylpolyglutamate hydrolase action. Folate availability
generally varies widely among foods. The maximum
availability is found in egg yolk (72·2 %) followed by
cow’s liver (55·7 %); there is a low availability from
vegetables (3–6 %). The absorption of folate from foods
varies from 25 % to 70 % with a mean close to about 50 %
(Tamura & Stokstad, 1973; Babu & Srikantia, 1976).
Synthetic folic acid (a stable oxidized form of pter-
oylmonoglutamate, often used to correct folate deficiency)
is considered to be more bioavailable than natural folate.
The bioavailability of supplements of folic acid under
fasting conditions are close to 100 % (Gregory, 1997).
Folic acid absorption in both pregnant and non-pregnant
Indian women was studied by Iyengar & Babu (1975) using
3H folic acid and 2 mg of cold folic acid. The absorption of
folic acid varied from 72 % to 94 % n  9 with a mean
absorption of 82 % which was similar to that obtained in
non-pregnant women n  6: On the other hand, food
folate is less bioavailable than the synthetic form
(Sauberlich et al. 1987; Cuskelly et al. 1996). It has been
recently demonstrated based on plasma folate that the
bioavailability of folate from spinach can be improved by
disruption of the vegetable matrix (vanhet Hof et al. 1999).
Currently, there are many accurate methods of estimat-
ing the food folate level and their bioavailabilities. The
procedures for the various methods of food folate
determination have been reviewed by Tamura (1998). It
is now well established that the ‘trienzyme method’ namely
alpha-amylase and protease for the extraction of folate
trapped in or bound to protein and carbohydrate matrices
and the enzyme folate conjugase for the hydrolysis of
polyglutamyl folate, be used to obtain the actual maximum
content of folate in each food item. According to Prinz-
Langenohl (1999) the AUC method with multiple blood
sampling is useful for assessing the availability of food
folate in humans. Using this method a significantly greater
absorption of 400 mg of folic acid than with the same
amount of food folate was reported in normal pregnant
women (Neuhouser et al. 1998). The use of a single dose,
dual-label, stable-isotope method was employed by Pfeiffer
et al. (1997) to assess the absorption of folic acid from
fortified cereal grain products. Isotope excretion ratios of
urinary folates that were used as criteria of availability,
indicated that the folic acid in these foods was highly
bioavailable. Thus it is evident that there is a need to
augment research in this area in India not only to generate
reliable food folate tables but also its availability to Indians
using these techniques.
Losses of food folate
Most natural folates are unstable and destroyed during
various cooking procedures and also by oxidation and
ultraviolet light (O’Broin et al. 1975; Dawson & Waters,
1994). Food processing can cause considerable losses of
folate for example in canning, in prolonged heating, when
cooking water is discarded and from reheating. Reducing
agents in food such as ascorbic acid provide greater
stability to the vitamin. Indian cooking practices such as
heating for prolonged periods in open vessels probably
destroy and reduce food folates considerably. Germination,
however, increases food folate availability (Babu, 1976a).
Folate status
Biochemical assessment of folate nutritional status is most
commonly done by measuring serum and RBC folate
levels. Serum folate essentially reflects recent intake and
Fig. 1. Folic acid distribution from different foods (mg/CU).
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red cell levels represent long term tissue stores. It is
generally accepted that serum folate values above 14 nmol/
L or RBC folate 360 nmol/L are considered to be
satisfactory; those between 7–14 nmol/L serum folate
and 320–360 nmol/L RBC folate are considered to be
low and suggestive of risk. Values lower than these indicate
clear deficiency of folate. Normal body stores are estimated
at 5–10 mg, half of which is in the liver. The turnover rate
is estimated to be less than 1 % per day. The measurement
of plasma concentrations of homocysteine is shown to be a
good indicator of folate and vitamin B12 status. A striking
negative correlation between serum folate and protein
bound homocysteine is reported (Kang et al. 1987).
Folate nutrition in Indians
There are no detailed studies on folate nutritional status in
the Indian population. However, there are some studies
which have been conducted in pregnant women (Raman
et al. 1989; Neela & Raman, 1997) indicating that folate
status may be poor in these vulnerable segments of the
population (Table 1). The folate nutriture in pregnant
women of low-income group who had not received any
antenatal care was reported by Raman et al. (1989). Based
on RBC folate levels, the folate deficiency during different
gestational periods ranged between 40·5 % and 53·3 %.
Considering the lower cut off used for defining per cent
deficient folic acid, these figures could be an underestimate
of the actual prevalence existing in poor communities.
Poor folate content of human fetal liver was reported by
Iyengar & Apte (1972). The mean total liver folate value
increased from 95 mg to 262 mg depending on the age of
the fetus (,28 to 37–40 wk). A study was carried out in
pregnant women belonging to the poor sections of the
population attending a local government hospital receiving
60 mg iron with or without folic acid and followed up from
20 to 24 weeks of pregnancy to term and 6 weeks
postpartum. The red cell folate levels decreased from
329 ^ 129 nmol=L at term to 256 ^ 118 nmol=L postpar-
tum in women who did not receive folic acid supplement.
The levels of red cell folate were not different from the
initial value in the group which received 100 mg folic acid
n  21: Significantly higher levels were observed only
with 200 mg n  25 and 300 mg n  23 of folic acid
supplementation; the increments were 91 nmol/L and
195 nmol/L respectively (Iyengar, 1971). A subsequent
study with 500 mg folic acid given with 60 mg iron showed
a reduction in the per cent of small for date births
(,2·5 kg) from 30 % to 16 % (Iyengar & Rajalakshmi,
1975). The red cell folate levels in infants born to mothers
who received 300 mg of folic acid were higher than those
born to the control group. The birth weights of infants born
to mothers who had received either 200 or 500 mg folic
acid daily were higher than those born to mothers who had
not received any supplements (Iyengar & Rajalakshmi,
1975). The above studies clearly indicate folate deficiency
in the population.
Etiology of folate deficiency
Folic acid deficiency can arise in a variety of settings such
as low dietary intake, increased demands during growth
periods (infancy and puberty), lactation and pregnancy,
malabsorption, conditions of hemolysis such as hemolytic
anemias and malignancy such as leukemias. Drug induced
folate deficiency is encountered in epileptics, ulcerative
colitis, etc. Chronic alcoholism is associated with folate
deficiency. Advanced folate deficiency, characteristically
produces macrocytic or megaloblastic anemia with hema-
tological features similar to vitamin B12 deficiency.
However, mucous membrane lesions and other clinical
manifestations such as neural tube defects (Lemire, 1988)
or more recently, hyper homocysteinemia with character-
istic vascular damage are well-recognized (Graham et al.
1997). Additional nutritional stress in pregnancy and during
infancy appears to be an important clinical problem that is
of public health significance. Folic acid may also be
associated with a variety of pregnancy complications such
as spontaneous abortions, bleeding, abruptio placenta and
pre-eclampsia.
The two important diseases in relation to folate status are
neural tube defects (NTD) and homocysteinemia. In recent
years, interest in plasma homocysteine has been growing
rapidly. Epidemiological data linking moderate elevations
in plasma homocysteine to higher prevalence of occlusive
Table 1. Folate nutriture of Indians†
No. RBC folate nmol/L Cutoff level nmol/L Per cent deficient
Men 45 323 ^ 97 180 8
(25–50 y)
Women 25 371 ^ 169 – –
(25–50 y)
Pregnant women 43 309 ^ 81 – –
,16 wk 60 310 ^ 153 284 53·3
17–20 wk 77 337 ^ 26 284 50·6
21–24 wk 84 348 ^ 175 284 40·5
25–28 wk 30 347 ^ 185 284 50·0
Pregnant women 115 287 ^ 117 284 25
(1 & 2 Trimesters)
Children (1–5 y) 246 267 ^ 90 180 20
(Boys & girls)
Values are means ^ SD.
† Ahmed et al. 1975; Babu, 1976b; Neela & Raman, 1997; Raman et al. 1989.
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vascular diseases such as coronary artery disease (CAD)
and stroke are now emerging.
Consequences of homocysteinemia
Folic acid is essential for the methylation of homocysteine
(Hcy) to form methionine and the biosynthesis of
deoxynucleotides needed for DNA replication. Increased
Hcy has been associated with premature vascular disease
(Boushey et al. 1995; Graham et al. 1997) and decreased
lymphocyte DNA methylation in postmenopausal women
(Jacob et al. 1998). Homocysteine has been implicated in
mental retardation in children, developmental defects,
occlusive disorders, osteoporosis and dislocated lenses
with lack of cystathionine betasynthase in the homozygous
state.
There is evidence that hyperhomocysteinemia is an
independent risk factor for ischemic heart disease (Wald
et al. 1998). The relative increase in risk of coronary heart
diseases for men and women respectively was 1·6 and 1·5
for each increment of 5 mmol/L in total plasma Hcy
(National Academy of Sciences, 1998; Boushey et al.
1995). These findings are in agreement with the Norwegian
Study relating prospective cardiovascular mortality risk to
elevated Hcy levels (Nygard, 1997).
The recent study on lowering blood Hcy with 400 mg
folic acid based supplements indicated that a daily intake of
400 mg of folate and 3 mg vitamin B6 may potentially help
reduce cardiovascular mortality (Rimm et al. 1998).
What is the current scenario in India?
There are no systematic studies on plasma Hcy levels. The
two preliminary studies on subjects with CAD show that
Hcy is not a strong risk factor (Chacko, 1998; Gheye et al.
1999). In both the studies the subjects belonged to the
middle socio-economic class. Serum Hcy levels were
similar in CAD patients and controls. The Hcy levels
varied from 2·98 to 63·36 mmol/L 10·98 ^ 9·04 in fifty-
six CAD patients and 3·74 to 19·62 mmol/L 9·41 ^ 3·60
in fifty-three control subjects (Chacko, 1998). Though the
mean (SE) total Hcy levels of 21·5 ^ 2·33 n  58 and
19·7 ^ 1·87mmol=L respectively in CAD patients and in
age and socio economic status matched controls was
comparable (Gheye et al. 1999), they were higher than the
upper cut off of the normal value of 7–17 mmol/L reported
for the Western population (Jacobsen, 1996). There is
evidence of greater vulnerability of South Asian migrants
in US to CAD and diabetes as compared to the native
populations. This increased susceptibility is reflected by the
prevalence of syndrome ‘X’ characterized by abdominal
obesity, hyperinsulinemia, hypertriglyceridemia, low con-
centration of HDL and hypertension. The high risk of CAD
in this population group is probably due to ‘X’ syndrome, a
consequence of fetal malnutrition (Gopalan, 1994). The
role of hyperhomocysteinemia as a risk factor in India
needs to be investigated.
Etiology of homocysteinemia
Homocysteine levels in plasma are determined by nutri-
tional, physiological, genetic and pathological factors
(Welch & Loscalzo, 1998).
Nutritional factors
Three vitamins of the B-complex group — folate, vitamin
B12 and riboflavin are involved in the different reactions of
Hcy metabolism. It is therefore, conceivable that the
deficiencies of these vitamins may influence the levels of
plasma Hcy. Well-documented evidence exists only for
folate. Studies in both animals and humans have shown that
folate deficiency is associated with marked elevation in
plasma Hcy levels (normal range 7–17 mmol/L) without
evidence of megaloblastosis and hypersegmentation of
neutrophil (Jacob et al. 1994). A strong negative correlation
between folate status and Hcy levels in plasma has been
observed. Subjects with even marginal deficiency of folate
(,7 nmol/L serum folate) have been found to have
elevated levels of Hcy suggesting that folate requirements
to correct this abnormality may be higher (Jacob et al.
1998). Elevated levels of plasma Hcy were also reported in
those over 80 years of age than in younger subjects (Selhub
et al. 1993; Tucker et al. 1996). Several recent studies show
reduction in Hcy levels on folate supplementation, both in
homocysteinemic subjects as well as normals (Homocys-
teine Lowering Trialists’ Collaboration, 1998; Dierkes et al.
1998; Malinow et al. 1998). These results suggest that folic
acid fortified cereals and supplements can certainly
decrease the plasma Hcy levels.
Physiological factors
Sex difference exists in plasma Hcy levels. Young women
(premenopausal) tend to have 25 % lower levels than men.
This difference decreases after menopause, perhaps sug-
gesting beneficial effects of female sex hormones. A strong
correlation between plasma estrodiol levels and Hcy in
post-menopausal women has been reported (Wouters et al.
1995). There is a progressive decrease in plasma Hcy levels
during pregnancy but the exact mechanism for this
reduction is not known. This has been attributed to lower
plasma albumin that binds Hcy and/or increased cortisol
level during pregnancy. Male sex and older age are thus
associated with hyperhomocysteinemia.
Genetic factors
Methylenetetrahydrofolate reductase (MTHFR) catalyses
the irreversible conversion of 5–10 methylene tetrahydro-
folate to 5-methyl tetrahydrofolate. Homozygous defi-
ciency of MTHFR due to a new type of point mutation of
the thermolabile MTHFR has been reported (Kang et al.
1988; Ma et al. 1997; Choi et al. 1999). A common
polymorphism of this gene, a specific C-T substitution at
nucleotide position 677 of the MTHFR gene (C677T)
causes the thermolability and reduced activity of this
enzyme. About 10 % of the urban Canadian population has
this defect suggesting a high frequency mutation (Frosst
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et al. 1995). These subjects have a 50 % reduction in the
activity of this enzyme and a tendency for higher levels of
plasma Hcy, particularly in individuals with low folate
nutritional status.
Life-style factors
A life-style profile characterized by low folate intakes,
smoking and high coffee consumption were the strongest
determinants of plasma Hcy concentrations. The folate
deficient tissues are thought to be more susceptible to
neoplastic transformation by carcinogens in the smoke
(Heinburger et al. 1988).
Drugs
Methotrexate is an antifolate drug that is widely used in the
treatment of acute leukemia and some solid tumors. Low
doses of this drug are also used in the management of
psoriasis and rheumatoid arthritis. Methotrexate is meta-
bolized intracellularly to polyglutamates and both the
parent drug and its metabolites inhibit dihydrofolate
reductase, the enzyme responsible for the conversion of
dihydrofolate to tetrahydrofolate. This results in the lower
folate level and impairment of folate functions at cellular
levels. Similar observation was made in children with acute
leukemia. Initially plasma Hcy levels were high and
chemotherapy with methotrexate as well as other cytotoxic
agents reduced Hcy level parallel to reduction in leukemic
cell count (Ueland & Refsum, 1989).
Anticonvulsant drugs like pheynytoin, phenobarbital,
premedian, carbamazepine cause folate deficiency (Els-
borg, 1974; Collins et al. 1988; Young & Ghadirian, 1989).
The proposed mechanisms include reduced folate absorp-
tion, increased metabolism of folate in the liver and altered
activities of some of the enzymes involved in one carbon
transfer.
Folic acid and cancer
Folic acid has been used as an antagonist for cancer therapy
for the last 40 years. An issue of interest is whether folic
acid deficiency is etiologically related to cancer specific
sites such as colorectal cancer (Giovannucci et al. 1993;
Choi & Mason, 2000). Folate deficiency is highly prevalent
in many developing countries where the incidence of
colorectal cancer is low, implying that other environmental
factors are probably responsible to enhance cancer risk.
There are studies to indicate that low red cell folate is
associated with increased risk of cervical dysplasia
especially carcinoma in situ (Butterworth et al. 1982).
High dietary intakes of folate along with vitamin C and
carotene have been observed to decrease the risk of
carcinoma in situ.
Neural tube defects (NTD)
Spina bifida and anencephaly are birth defects of multi-
factorial etiology related to neural tube closure. Anence-
phaly is characterized by the absence of forebrain and spina
bifida is characterized by incomplete fusion of the vertebral
arches with protruding sac with meninges, spinal cord and
nerve roots. The role of folic acid in reducing the rate of
NTD has been well-established (National Academy of
Sciences, 1998). Pre-conceptional administration of folic
acid can reduce women’s risk of having a fetus or infant
with a NTD. Several observational studies and randomized
trials suggest that peri-conceptional folic acid supplemen-
tation lowers the risk of neutral tube defects and currently,
the consensus is that all women of child bearing age must
consume 400 mg of folic acid per day to reduce their risk of
having a child with NTD (Berry et al. 1999; Cuskelly et al.
1996; de Bree et al. 1997; Scott et al. 1994).
Prevalence
There is significant geo-ethnic variation in the prevalence
of NTDs worldwide (Table 2). In United States a decrease
in the prevalence of NTDs at birth has been reported. The
current rates vary from 0·72 to 1·03 per 1000 births in
different states (National Academy of Sciences, 1998). It
has been pointed out that anencephaly is relatively
uncommon in people with African origin while it is very
common in Northern Ireland and Wales (6·38 to 10·9/1000
births) (Lemire, 1988). The other population with high rates
of NTDs includes the Northern Chinese population (Berry
et al. 1999). The difference in the NTD in northern and
southern regions of China suggests that factors other than
ethnic background may have a role.
In India, large-scale epidemiological studies have been
conducted to determine prevalence of NTD (Table 2). In
general, the prevalence of NTDs is considerably high and
varies in different parts of the country (Sharma & Gulati,
1992; Agarwal, 1998). Southern India and the Western
parts of the country apparently have lower rates except
Davangere in Karnataka where the prevalence is quite high
at 11·4/1000 births (Kulkarni et al. 1989). Data from a
teaching hospital in Lucknow indicates a prevalence of 4·7/
1000 births (Agarwal et al. 1991).
Table 2. Frequency of neural tube defects in India, USA, Canada,
UK and China
India†
NTD 1000
births
USA and
Canada‡
NTD 1000
births
Amritsar 8.0 Arkansas 1.03
Jaipur 5.6 Atlanta 0.99
Udaipur 7.8 California 0.94
Chandigarh 12.0 Iowa 0.90
Delhi 4.1 Hawaii 0.92
Lucknow 4.7 Quebec 1.41
Rajasthan 18.0
Ajmer 6.6
Calcutta 1.1 UK§
Patna 5.3 Northern Ireland 6.38
Mumbai 2.2 Wales 10.9
Chennai 2.3 China¶
Mysore 1.5 Northern region 6.5
Davangere 11.4 Southern region 0.8
Wardha 3.9
† Sharma & Gulati, 1992; Kulkarni & Jose, 1997; Kulkarni et al. 1989.
‡ National Academy of Sciences (1998). §Lemire 1988. ¶Berry et al. 1999.
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Etiology
Etio-pathogenetically, NTD is a heterogenous entity and is
multifactorial in origin (Dolk et al. 1991) with a strong
genetic component (Emery, 1986). It is believed to be
polygenic, probably involving multiple genes. The high
prevalence of NTDs in certain parts of India has been
attributed to high rates of consanguinity (Kulkarni et al.
1989). The dengue viral infection has also been suggested
as a possible factor by Sharma & Gulati (1992) based on
the cluster of NTDs that appeared in the Rohtak district of
Haryana, India. Several other factors such as previous fetal
loss, maternal epilepsy, teenage pregnancy, rubella, dia-
betes and poor socio-economic status have been reported to
increase the risk of NTD. The incidence of NTD is high in
the Sikh community (Stevenson et al. 1966; Chambers et al.
1994).
Among the environmental factors, nutrition has been
identified as an important contributor to this disease. The
lower the plasma folate, the higher is the number of NTDs,
the picture with respect to erythrocyte folate is similar. The
reduction in risk of neural tube defects by folic acid
supplementation has been conclusively shown in controlled
intervention trials (Scott et al. 1995; Locksmith & Duff,
1998). The mechanism by which adequate folate intake
reduces the risk during the crucial developmental phase of
the embryonic neural tube is unknown. Increasing folate
intake, which increases the concentrations of folate co-
enzymes in tissues, may overcome an unidentified meta-
bolic defect at the time of neural tube development and
closure (National Academy of Sciences, 1998).
Control of neural tube defects
Results of several double blind randomized trials support
the beneficial effect of folic acid supplementation in
reducing the incidence of NTD (Laurence et al. 1981;
National Academy of Sciences, 1998). The Medical
Research Council of Great Britain conducted an interven-
tion study in women with previous history of NTD and
showed a 72 % reduction in the risk of having an affected
fetus or infant in women who took 400 mg folic acid (MRC
Vitamin Study Research Group, 1991). A 30–40 %
reduction in NTD-affected pregnancies among women
whose average dietary intake of methionine was above the
lowest quartile of intake (.1·34 g/d) was reported by Shaw
et al. (1997). A recent study from China (Berry et al. 1999)
suggests that the daily ingestion of 400 mg of folic acid
alone during the periconceptional period may help reduce
the rate of the first occurrence of NTDs in many parts of the
world. The risk can be considerably decreased by
increasing the folate intake to 400–500 mg while planning
pregnancy and continuing upto the twelfth week of
pregnancy. Periconceptional folate supplementation has
been encouraged in the UK since the early 1990s, but no
concurrent decline in NTD pregnancies has been observed
by regional congenital anomaly registers (Abramsky et al.
1999).
Currently, food fortification is implemented for preven-
tion of NTD (Bailey, 1998). Considering the strong
association of folic acid and NTDs and low intake of
food folate of 110–140 mg/d as against an RDA of 200 mg/
d by the women of child bearing age in the United States,
fortification of cereal-grain products with folic acid is
mandated by the FDA. It has been estimated that the level
of folic acid fortification of 140 mg/100 g cereal-grain
product recommended by the FDA would increase folic
acid intake by 80–100 mg/day in this group of women.
Consequently, as of 1 January 1998 cereal-grain products in
the US food supply are being fortified with folic acid to
prevent NTDs (Malinow et al. 1998).
In India there are no such studies demonstrating the
beneficial effects of folic acid supplementation on preven-
tion of NTDs. The limited Indian experience also shows
that folic acid can prevent NTD (Kulkarni & Jose, 1997). It
is, however, pertinent to mention that a National Nutritional
Anemia Control Programme for pregnant women has been
in operation since 1970 which envisages a supply of 60 or
100 mg of iron with 500 mg folic acid per day for 100 days
(Ministry of Health and Family Welfare, 1970; Indian
Council of Medical Research, 1989; Indian Council of
Medical Research, 1992). An evaluation in eleven States
during 1985–86 indicated very poor coverage and perfor-
mance of the programme. The folic acid content in these
tablets was 35 % or less than the expected level
(Vijararaghavan et al. 1990). To what extent the above
programme contributes to folate nutriture under the
programmatic conditions is not known. Thus, there is a
need to have countrywide data on folate status, food folate
levels, and bioavailability to facilitate intervention
measures.
Recommended dietary intake of folate
Folate requirements have been defined as the quantity of
intake necessary to prevent severe deficiency with clinical
symptoms (National Academy of Sciences, 1989). Cur-
rently, the focus has shifted to identifying intakes
associated with maintenance of normal biochemical func-
tion such as one-carbon transfer reactions. Abnormalities
identified in the metabolic pathways such as hyperhomo-
cysteinemia, hypomethylation of DNA and uracil mis-
incorporation are assigned as functional indicators of folate
status (Selhub et al. 1993; Green & Jacobsen, 1995; Blount
et al. 1997; Jacob et al. 1998). Risk reduction for chronic
diseases and developmental defects (NTD) have also been
used for deriving optimum folate intakes (Boushey et al.
1995; Daly et al. 1997). Stable isotopically labeled folate is
also used in defining the folate requirement more
accurately (Gregory et al. 1998).
Based on recent studies, the National Academy of
Sciences (1998) have reported new dietary reference
intakes (DRI) for folate. The DRI for folate includes folate
requirement estimation for population groups referred to as
the estimated average requirement (EAR). EAR is defined
as the amount of folate that is needed to meet the
requirement of 50 % of the population. The recommended
dietary allowances (RDA) were derived from the EAR by
correcting for population variance which is defined as the
average level of daily dietary intake to meet the require-
ment of 98 % of the population. The basis for deriving
EAR and RDA for folate was mainly based on the study of
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O’Keefe et al. (1995). The DRIs for folate are expressed as
Dietary Folate Equivalents (DFE), a term used to adjust for
the generally higher bioavailability of synthetic folic acid
relative to most forms of naturally occurring folate in foods
(National Academy of Sciences, 1998; Bailey, 1998). It is
estimated that 85 % of synthetic folic acid is bioavailable
when consumed with food, while the bioavailability of food
folate as such is only 50 % that of synthetic folic acid.
For male and female adults over 19 years of age, the
folate EAR and RDA are 320 and 400 mg DFE/d
respectively (Table 3). For pregnant women, the corre-
sponding figures are 520 and 600 mg DFE/d. Subsequent
studies with folate intake of 600 mg DFE/d were shown to
be adequate to maintain normal folate status in pregnant
women (Bonnette et al. 1998; Caudill et al. 1997; Caudill
et al. 1998).
The current RDA for folate in Indians is based on the
following literature evidences. The free and total folate
levels in Indian foods have been determined microbiolo-
gically using L. casei as the organism (Gopalan et al.
1989). Studies on the actual availability of food folate are
few. Dietary surveys in Indian subjects show that
predominantly cereal based diets provide about 70 mg
folic acid a day (NNMB, 1999). The bioavailability of
folate from a typical Indian diet varied from 60 to 70 % in
pulses and green leafy vegetables and about 50 % in
vegetables (Babu & Srikantia, 1976). In a repletion-
depletion study in Indian human volunteers, 75 mg of
folate was found to be adequate to maintain optimal
concentrations of folate both in serum and red blood cells
(Babu, 1976b). Based on this, the safe level of folate intake
was fixed at 100 mg/day. Due to lack of precise informa-
tion on bioavailability of food folates, the ICMR Commit-
tee had recommended a RDA of 100 mg of free folate for
adults (Table 4). The results of the study of Iyengar (1971)
in Indian women have suggested that between 200 and
300 mg of folates are needed to maintain plasma and red
cell folate in the normal range during pregnancy. Based on
this, an amount of 400 mg/day of additional folic acid is
suggested for pregnant women. The estimated folate
content of breast milk secreted by Indian women is
16 mg/L (Ramasastry, 1965) which is twice as low as that
reported from the west. Therefore, an additional allowance
of 50 mg of folate is recommended (150 mg/d) for lactating
women (Indian Council of Medical Research, 1989).
The dietary intake of folate in different countries varies
considerably from 100 to 300 mg/d. The most recent Indian
data from the NNMB (1999) indicate that the mean folate
intake is around 150 mg (Fig. 1, Table 4) and appears to
meet the RDA. However, the intake of folic acid was less
than the RDI of 200 mgm/d in all states, except Gujarat.
The intakes are also much higher in other countries
compared to India (Table 3).
Even though the minimum requirements are around 50 to
150 mg considering the factors such as individual varia-
tions and bioavailability, the recommendations are in the
range of 170–320 mg of food folate (Table 3). However, as
stated earlier, the desired folate intake would have to be
much higher than these levels to reduce the prevalence of
some of the more recent clinical situations (Table 5). As it
is difficult to obtain the adequate level of folate from food,
the entire western world has initiated implementation of
food fortification, this being the most cost-effective way of
reducing the adverse health effects of folic acid (Malinow
et al. 1998; National Academy of Sciences, 1998).
The recommended folate intake needs revision in the
Indian context. Though promoting voluntary use of folate
supplementation is a potential short-term strategy, it is
difficult to implement in the Indian situation. In addition to
pharmacological approaches, we therefore also need to
think in terms of food fortification. These potential
Table 3. Recommended dietary intake (RDI) (mg/d)† for folate for the adult population
Recommended
Country Minimum requirements Individual variation Bioavailability Male Female
FAO/WHO 60 +15 % +70 % 200 170
USA +20 % +50 % 320‡ 320‡
UK 100 +? +50 % 200 200
The Netherlands 50 +200–300 % +50 % 200–300 200–300
France 50 ? ? 300 300
Germany 150 ? +50 % 300 300
India 75 ? +50 % 100 100
† de Bree et al. 1997; National Academy of Sciences (1998); Indian Council of Medical Research, 1989. ‡Dietary folate equivalents (DFE).
Table 4. Recommended dietary allowances of folic acid in Indians
and current intake of folate
RDA mg of free
folate/day†
Current RDI
mg/day‡
Men 100 182·0
Women 100 154·9
Pregnant women 400 145·7
Lactating women 150 165·5
Infants
0–12 months 25 –
Children
1–3 y 30 57·5
4–6 y 40 93·5
7–9 y 60 115·4
Boys, Girls
10–12 y 70 133·2
126·1
13–15 100 148·2
142·4
16–18 100 178·2
144·0
† Indian Council of Medical Research, 1990. ‡NNMB National Nutrition
Monitoring Bureau, 1999.
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interventions need careful consideration for feasibility,
sustainability and effectiveness under programmatic con-
ditions.
Conclusions
Currently from the dietary intake studies and folate status in
pregnant women and children, it has been observed that the
incidence of sub-clinical forms of folic acid deficiency is
high. Therefore, there is a need for a concerted effort to
adopt strategies for preventing NTDs and possibly
cardiovascular complications in the adult population.
Clinical issues that need consideration relate to an
appropriate analogue of folic acid, the stability and cost,
its trade and regulatory issues, mechanisms to reach those
at high risk, the vehicles which need to be fortified, its
procurement, processing and distribution of the same
coupled with its quality assurance and control. It must be
borne in mind that in addition to the deficiency of iron and
other major micronutrients, folic acid has to be given due
importance and appropriate steps must be initiated for
prevention and control of its deficiency.
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